抗发作疗法减轻了阿尔茨海默病的认知衰退:一个回顾性队列研究
Katsunori Yokoi1,2,3, Masashi Tsujimoto1,2,4, Keisuke Suzuki1,2,3,4
1Department of Neurology, National Center for Geriatrics and Gerontology, Obu City, Aichi Prefecture, Japan.
Journal of Alzheimer's disease : JAD
|January 22, 2026
概括
抗发作药物治疗可以改善阿尔茨海默病 (AD) 患者的认知功能. 这种益处在轻度至中度认知障碍 (MMSE 22-26) 的患者中最为明显.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 临床医学 临床医学
背景情况:
- 发作和型活动在阿尔茨海默病 (AD) 中很常见,可能加速认知衰退.
- 抗发作药物 (ASM) 治疗对阿尔茨海默病患者认知轨迹的影响尚不清楚.
研究的目的:
- 评估ASM治疗对AD和并发性患者认知轨迹的影响.
- 确定特定的患者亚组,他们可能从ASM治疗中获益最多.
主要方法:
- 对538名患者的回顾性研究 (仅有403名AD,有135名患者) 接受了新一代ASM治疗.
- 在24个月内使用迷你精神状态检查 (MMSE) 评估认知功能.
- 分析包括线性混合效应建模和倾向性得分匹配,根据基线MMSE得分分层分.
主要成果:
- 倾向性得分匹配确保了群体之间平衡的基线特征.
- 在基线MMSE得分在22-26之间,在MMSE25达到峰值的患者中观察到特定亚组的相互作用.
- 与仅患有AD的患者相比,患有AD和的患者在12个月后显示出更高的MMSE得分 (23.23对20.33) 和24个月后的边界显著差异 (22.92对19.36).
结论:
- 抗发作疗法似乎与AD患者的良好的认知轨迹有关.
- 观察到最显著的益处是在基线MMSE得分在22和26之间的患者身上.
- 这些发现表明,在阿尔茨海默病中,ASM可能是一个潜在的治疗窗口,需要通过前性研究来确认.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...


